Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHammerson Regulatory News (HMSO)

Share Price Information for Hammerson (HMSO)

Share Price is delayed by 15 minutes
Get Live Data
330.60    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.20 (0.364%)
Market Cap: £1.75b
HMSO Live PriceLast checked at - London Stock Exchange

Intraday Hammerson Share Chart

Hammerson Completes Refinancing Transactions

9 Oct 2024 07:00

RNS Number : 4219H
Hammerson PLC
09 October 2024
 

9 October 2024

Hammerson plc

("Hammerson" or the "Company/Group")

Hammerson completes refinancing transactions to underpin growth strategy

Following the successful issuance of its 12-year £400m bond, Hammerson sets out the final outcome of the new issuance and accompanying tender of the Company's outstanding bonds maturing in 2026 and 2028:

· 12-year £400m bond pricing confirmed on 3 October at a coupon of 5.875% representing a spread of 183 basis points over the reference gilt rate

· Strong demand led to peak order book in excess of £2.6bn (over 7x subscribed)

· The repurchase of a total of £411.6m bonds, comprising £168.4m of 6% 2026s and £243.2m of 7.25% 2028s

· An annualised net interest benefit to Hammerson of £3.6m1 per year (approximately £0.8m for the financial year ending 2024)

· This reduces weighted average gross interest from 3.8%2 to 3.6% and extends Hammerson's weighted average debt maturity from 2.9 years3 to 5.2 years

· The refinancing is largely leverage neutral; pro forma4 LTV at 30 June 2024 is 25.5% and net debt:EBITDA is 5.4x

 

Himanshu Raja, CFO of Hammerson plc, commented:

"The combined effect of our new £400m 5.875% bond maturing in 2036 and the tender of our existing short-dated sterling maturities reduces our ongoing interest costs and extends our weighted average debt maturity. The strong demand and competitive pricing are a clear recognition from investors of the strength of our portfolio, the robust balance sheet and the opportunity ahead of us."

 

1 Annualised interest benefit arises due to the weighted average interest cost on the bonds tendered (6% on 2026s and 7.87% on 2028s) being 7.1% and higher than the 5.875% coupon on the new issue, offset by the impact of new issue discounts and the reduction to interest receivable due to net cash outflows.

2 Weighted average gross interest rate at 30 June 2024 of 3.4% and pro forma for the refinancing of Dundrum in August 2024 of 3.8%.

3 Weighted average debt maturity at 30 June 2024 of 2.2 years and pro forma for the refinancing of Dundrum in August 2024 of 2.9 years. 

4 Pro forma for the tender and new issuance financing transactions and the disposal of the Group's interest in Value Retail generating net proceeds of £583m. Pro forma at 30 June 2024 reflecting only the disposal of the Group's interest in Value Retail; LTV was 24.7% and net debt:EBITDA was 5.3x.

 

ENDS

Hammerson plc

Investor Contact

Josh Warren, Hammerson, Director of Strategy, Commercial Finance and Investor Relations

 

 

 

+44 (0)20 7887 1053

MHP for Hammerson Media

Oliver Hughes

Ollie Hoare

 

+44 (0)7885 224 532

+44 (0)7817 458 804

 

 

The announcement above has also been released on the SENS system of the Johannesburg Stock Exchange and on Euronext Dublin.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZMGGKRNGDZM
Date   Source Headline
5th Jun 20268:00 amRNSPublication of Final Terms
2nd Jun 20267:00 amRNSSuccessful pricing of 5-year EUR350m bond
29th May 20263:45 pmRNSHolding(s) in Company
26th May 202610:00 amRNSResults of Dividend Reinvestment Plan
22nd May 20264:15 pmRNSDirector/PDMR Shareholding
19th May 20262:00 pmRNSDirector/PDMR Shareholding
15th May 202612:30 pmRNSDirector/PDMR Shareholding
14th May 20263:00 pmRNSDirector/PDMR Shareholding
30th Apr 20264:30 pmRNSTotal Voting Rights
30th Apr 202611:15 amRNSResult of AGM
30th Apr 20267:00 amRNSHammerson CFO to retire
29th Apr 20267:00 amRNSHolding(s) in Company
28th Apr 20263:00 pmRNSDirector/PDMR Shareholding
24th Apr 20261:30 pmRNSEMTN Programme: Publication of Base Prospectus
24th Apr 20267:00 amRNSHolding(s) in Company
23rd Apr 20267:00 amRNSHolding(s) in Company
8th Apr 20264:00 pmRNSDirector/PDMR Shareholding
7th Apr 202612:45 pmRNSTotal Voting Rights and Capital
30th Mar 202610:00 amRNSDirector/PDMR Shareholding
26th Mar 202611:00 amRNSAnnual Report and Notice of Annual General Meeting
19th Mar 20262:00 pmRNSDirector/PDMR Shareholding
17th Mar 202610:00 amRNSDirector/PDMR Shareholding
17th Mar 20269:00 amRNSDividend Currency Conversion Announcement
25th Feb 20267:01 amRNSDividend Declaration
25th Feb 20267:00 amRNSFinal Results
6th Feb 20267:00 amRNSDirectorate change
28th Jan 20269:00 amRNSNotice of Results
20th Jan 20263:30 pmRNSHolding(s) in Company
22nd Dec 202511:30 amRNSDirector/PDMR Shareholding
22nd Dec 20259:30 amRNSDirector/PDMR Shareholding
15th Dec 20253:00 pmRNSDirector/PDMR Shareholding
11th Dec 20252:15 pmRNSTotal Voting Rights
11th Dec 20252:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSDirectorate change
21st Nov 20257:00 amRNSAcquisition of The Oracle and Trading Update
13th Nov 20251:45 pmRNSDirector/PDMR Shareholding
31st Oct 20257:45 amRNSResults of Dividend Reinvestment Plan
28th Oct 20251:00 pmRNSDirector/PDMR Shareholding
24th Oct 20254:00 pmRNSDirector/PDMR Shareholding
23rd Oct 202511:00 amRNSDirector/PDMR Shareholding
22nd Oct 20254:30 pmRNSDirector/PDMR Shareholding
21st Oct 202512:00 pmRNSDirector/PDMR Shareholding
16th Oct 20251:00 pmRNSPublication of Final Terms
9th Oct 20257:00 amRNSBond Pricing, Guidance & Operational Update
25th Sep 20254:30 pmRNSHolding(s) in Company
19th Sep 20253:30 pmRNSDirector/PDMR Shareholding
11th Sep 20254:45 pmRNSHolding(s) in Company
9th Sep 20257:00 amRNSAppointment of Rob Wilkinson as CEO
4th Sep 20253:30 pmRNSPublication of Supplementary EMTN Prospectus
29th Aug 202512:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.